Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug;60(10):3320–3331. doi: 10.1167/iovs.18-25647

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2019 The Authors

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

PMC Copyright notice

Treatment with VP1-001 significantly reduces cataract grade in cryAB(R120G) mutant mice, but ent-VP1-001 is inactive. (A) Cataract grading for cryAB(R120G) heterozygous mice treated with either compound. The vehicle group represents combined contralateral eyes from both treatment groups. (B) Age distribution of cryAB(R120G) heterozygous mice separated by treatment condition. Each point represents an individual mouse lens. The mean is shown by a dotted line, and the error bars represent the standard errors from the means. (C–H) Representative slit lamp images from a cryAB(R120G) heterozygous mouse showing the extent of lens opacity in vehicle-treated (C) and ent-VP1-001–treated eyes (D). Representative slit lamp images from a cryAB(R120G) heterozygous mouse showing the extent of lens opacity in vehicle-treated (E) and VP1-001–treated eyes (F). Representative slit lamp images from a cryAB(R120G) heterozygous mouse showing the extent of lens opacity in an untreated eye (G). Representative slit lamp images from an untreated normal, WT mouse showing a clear lens (H).